{{Rsnum
|rsid=503362
|Gene=PGR
|Chromosome=11
|position=101091096
|Orientation=plus
|GMAF=0.2135
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=PGR
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 2.7 | 43.8 | 53.6
| HCB | 0.0 | 0.7 | 99.3
| JPT | 0.0 | 2.7 | 97.3
| YRI | 11.6 | 49.0 | 39.5
| ASW | 0.0 | 0.0 | 0.0
| CHB | 0.0 | 0.7 | 99.3
| CHD | 0.0 | 0.0 | 0.0
| GIH | 12.1 | 30.3 | 57.6
| LWK | 12.1 | 37.4 | 50.5
| MEX | 1.8 | 26.8 | 71.4
| MKK | 0.0 | 0.0 | 0.0
| TSI | 10.9 | 46.5 | 42.6
| HapMapRevision=28
}}
[http://www.medpagetoday.com/MeetingCoverage/SMFM/12729 news]  The effectiveness of [[17 alpha-hydroxyprogesterone caproate]] for prevention of recurrent preterm birth is influenced by SNPs.

Black women
*[[rs471767]] homozygous for the major allele treatment significantly reduced the rate of preterm birth.
*[[rs578029]] who had a least one copy of the major allele, treatment significantly reduced in preterm birth

non-black women
*a least one copy of the minor allele of [[rs503362]] had a significant reduction with treatment
*with at least one copy of the minor allele of [[rs666553]] had a significant reduction in very preterm birth

{{PMID Auto
|PMID=21600550
|Title=Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate
|OA=1
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}